Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Russian Journal of Pediatric Hematology and OncologyOpen Access

Results of therapy for relapse associated with the loss HLA of heterozygosity in children with acute leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

PKP. V. KozhokarLTL. A. TsvetkovaAEA. V. Evdokimov

Discussion

Loading...

Member takes

Overview

Analysis of immunotherapy approaches shows second allo-HSCT improves overall survival in children with HLA LoH relapse.

Key Points

  • Second allo-HSCT resulted in a significant 71.4% overall survival rate for patients with HLA LoH relapse.
  • In comparison, patients not undergoing second allo-HSCT showed a 26.3% overall survival, indicating a possible treatment benefit.
  • The study analyzed outcomes of 26 children with HLA LoH relapse after allo-HSCT, focusing on various therapeutic strategies.
  • Results suggest that targeted approaches based on HLA LoH status may optimize therapy and improve survival rates.

Cite This Study

Kozhokar et al. (2025) studied this question.

synapsesocial.com/papers/68c23e02b210217d6478fde9https://doi.org/10.21682/2311-1267-2024-11-4-35-43
View Full Paper
Ask AI
Bookmark
Share